Researchers Test Nintedanib in Mesothelioma Clinical Trial

Research & Clinical Trials
Reading Time: 3 mins
Publication Date: 09/16/2016
Fact Checked
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Reviewed

Asbestos.com is the nation’s most trusted mesothelioma resource

The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.

Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.

More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.

About The Mesothelioma Center at Asbestos.com

  • Assisting mesothelioma patients and their loved ones since 2006.
  • Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
  • A+ rating from the Better Business Bureau.
  • 5-star reviewed mesothelioma and support organization.
Learn More About Us

Testimonials

"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."
Lashawn
Mesothelioma patient’s daughter
  • Google Review Rating
  • BBB Review Rating

How to Cite Asbestos.com’s Article

APA

Povtak, T. (2020, October 16). Researchers Test Nintedanib in Mesothelioma Clinical Trial. Asbestos.com. Retrieved October 6, 2022, from https://www.asbestos.com/news/2016/09/16/nintedanib-mesothelioma-clinical-trial/

MLA

Povtak, Tim. "Researchers Test Nintedanib in Mesothelioma Clinical Trial." Asbestos.com, 16 Oct 2020, https://www.asbestos.com/news/2016/09/16/nintedanib-mesothelioma-clinical-trial/.

Chicago

Povtak, Tim. "Researchers Test Nintedanib in Mesothelioma Clinical Trial." Asbestos.com. Last modified October 16, 2020. https://www.asbestos.com/news/2016/09/16/nintedanib-mesothelioma-clinical-trial/.

Medical oncologist Dr. Rama Balaraman isn’t expecting any miracles from the pleural mesothelioma clinical trial involving nintedanib, the small-molecule enzyme inhibitor.

She is expecting progress.

Balaraman, at Florida Cancer Affiliates in Ocala, is participating in an international, multicenter trial that will expand the use of nintedanib within the U.S., giving patients another weapon in this fight against mesothelioma cancer.

“It is potentially a new way of approaching [this disease], and it’s causing a lot of excitement,” Balaraman told Asbestos.com. “We are hopeful.”

Nintedanib, also known by brand name Ofev, already is administered in the U.S. for treatment of idiopathic pulmonary fibrosis. The drug relieves breathing problems by softening the lungs. The U.S. Food and Drug Administration (FDA) approved its use in 2014.

This phase II/III trial evaluates its safety and effectiveness for use alongside chemotherapy agents pemetrexed and cisplatin. Researchers hope it will increase the effectiveness of chemotherapy.

Pleural mesothelioma is a rare and aggressive cancer that starts in the thin membrane surrounding the lungs. It is caused by inhalation of microscopic asbestos fibers that become lodged in that membrane, causing inflammation, scarring and eventually, leading to cancer that can metastasize throughout the thoracic cavity.

A chemotherapy regimen, which works only sporadically and is not sustainable, is the most used standard-of-care treatment. Although therapies have improved in recent years, the typical patient with pleural mesothelioma still has a life expectancy of only 6-21 months after diagnosis.

Oncologists in Europe Already Administer Nintedanib

In Europe, oncologists administer nintedanib with chemotherapy to treat lung cancer, but the FDA has not approved it for that use in the United States. Clinical trial investigators are hoping this study can move nintedanib toward approval for various cancers, including mesothelioma.

“These clinical studies are important. [They’re] the only way you can move treatment forward,” Balaraman said. “Sometimes you take baby steps, and sometimes it’s a giant baby. You don’t know what drug will be a baby step, and what drug will be that giant baby. Often, it’s a combination of two baby-step drugs that make the giant baby.”

Boehringer Ingelheim, a German-based pharmaceutical company, produces the drug and steers the mesothelioma clinical trial in 23 different countries.

U.S. locations include San Francisco, Colorado Springs, Houston; Henderson, Nevada, and various satellite sites.

The study is a double-blind and placebo-controlled trial aimed at those with unresectable pleural mesothelioma. Patients with epithelioid and biphasic cell types are eligible for enrollment. The estimated completion date is October 2019.

Previous studies show nintedanib can inhibit tumor cell proliferation and migration, along with obstructing key enzymes that cause tumors to develop new blood vessels. It can block multiple pathways involved in the scarring of lung tissue.

Cancer Centers in US & Europe Testing Nintedanib

There are several ongoing clinical trials involving nintedanib in the U.S. and Europe.

  • Karmanos Cancer Institute in Detroit: Researchers are in the midst of a phase II study of nintedanib for patients with recurrent pleural mesothelioma to assess overall survival improvement with the drug for those who finished their chemotherapy regimen.
  • University of Michigan Comprehensive Cancer Center in Ann Arbor and the University of California Davis Cancer Center in Sacramento: Both centers will soon begin recruiting patients as part of the Karmanos study.
  • Gustave Roussy cancer center in France: Researchers already are recruiting patients for a phase I study of mesothelioma involving nintedanib with pembrolizumab, an immunotherapy drug also known as Keytruda.

“These types of drugs [like nintedanib] have multiple mechanisms of action,” Balarama said. “It’s a new way of approaching [mesothelioma] treatment. And there is a lot of excitement about it right now.”

Connect with a Mesothelioma Doctor
Find a Top Specialist Near You